Q-omics provides the consensus-scored MEGF6 profile across patient tissues and cancer cell-line models. MEGF6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MEGF6 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MEGF6 RNA expression shows 18,764 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where MEGF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEGF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEGF6 survival associations across molecular data types. MEGF6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEGF6 RNA expression–survival associations across cancer types. High MEGF6 expression shows unfavorable associations in THCA, COAD and LGG, but favorable associations in HNSC, BLCA and DLBC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MEGF6 RNA expression.
This table summarizes MEGF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MEGF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEGF6 shows lower tumor expression in KICH, LUAD and UCEC and higher tumor expression in COAD, KIRC and STAD. The COAD box plot shows higher MEGF6 RNA expression in tumor versus normal tissue (log2 FC = +2.138, t-test p < 0.001).
This table shows molecular features associated with MEGF6 in patient tissues and cancer cell lines. In patient samples, MEGF6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MEGF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
